Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Top Cited Papers
- 1 July 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (19), 2660-2666
- https://doi.org/10.1200/jco.2010.32.4145
Abstract
Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in precl...This publication has 36 references indexed in Scilit:
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2010
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2010
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceNeuro-Oncology, 2010
- Concerns about anti-angiogenic treatment in patients with glioblastoma multiformeBMC Cancer, 2009
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2009
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesisEndocrine-Related Cancer, 2007
- Prognostic value of codon 918 (ATG?ACG)RET proto-oncogene mutations in sporadic medullary thyroid carcinomaInternational Journal of Cancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000